Categories: All postsSoftware

Pethealth soars on Fairfax takeover bid despite CEO opposition

Shares of Pethealth (Pethealth Stock Quote, Chart, News: TSX:PTZ) are up more than 25% today after the company said it had entered into an arrangement agreement with Fairfax Financial that would see that company acquire Pethealth for $2.79 a share, a price that values it at $100-million and is a 26% premium to its August 29th closing price.

The company’s board says it recommends shareholders tender their shares to the offer. The deal has already received narrow approval, with 50.9% of outstanding shares and 65.2% of preferred shares having entered into voting support agreements.

One notable opponent is CEO Mark Warren, who owns approximately 9.7 per cent of Pethealth, and has voted against approval of the transaction.

At least one analyst believes Pethealth could be worth more than Fairfax Financial’s offer. In late August, following the company’s announcement that it was “reviewing strategic alternatives for the potential sale of the company”, Industrial Alliance analyst Fred Westra conducted a sum-of-the-parts valuation of Pethealth.

The analyst compared Pethealth’s insurance business to peer Trupanion (Trupanion Stock Quote, Chart, News: NYSE:TRUP) and arrived at a value of between $60-$80million or $1.73-$2.27 per share. He compared its microchip and database business to U.K.-based Animalcare PLC (Animalcare PLC Stock Quote, Chart, News: LON: ANCR) to assign a value of more than $35-million, or $1.00 per share. And he believes the company’s Petango brand and ecommerce business was worth about $20-million, or $0.57 a share based on transactions by Discovery Communications (Discovery Communications Stock Quote, Chart, News: NASDAQ:DISCA), by Nestle Purina, and by PetSmart (PetSmart Stock Quote, Chart, News: NASDAQ:PETM). Westra’s valuation has him arrive at a price of $3.34 for Pethealth, but he said he could see upside as a high as $4.00 per share. The analyst, however, maintained his $2.50 one-year target on the stock, based on the assumption that it would remain independent.

The Pethealth shareholder meeting will take place in November.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: ptz
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

2 days ago

Is SNAP a buy right now?

He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]

2 days ago

Bombardier wins price target raise at Desjardins

Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]

2 days ago

Rogers is an undervalued stock, RBC says

With the integration of Shaw Communications underway, RBC analyst Drew McReynolds says Rogers Communications (Rogers Communications Stock Quote, Chart, News,… [Read More]

3 days ago

Tornado Global Hydrovacs is still a double, Beacon says

Following fourth quarter results he describes as "stronger than expected", Beacon Securities analyst Russell Stanley has raised his price target… [Read More]

4 days ago

Sell your Molson Coors stock, Citi says

Ahead if its first quarter results, Citi analyst Filippo Falorni says there is not much to like about Molson Coors… [Read More]

4 days ago